NWPHF 財務： Newron Pharmaceuticals SpA AI 分析

首頁

股票

NWPHF

財務狀況

NWPHF 財務

Newron Pharmaceuticals SpA

0%

$0

收盤價：Mar 27, 16:00:00 GMT-4

0%

$0

盤後：Mar 27, 20:00:00 GMT-4

概觀預測收益股利財務狀況

關鍵數據

前收市價

開盤價

當日範圍

52週區間

交易量

平均成交量

股息收益率

每股盈餘 (TTM)

市值

什麼是 NWPHF？

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

功能特性

資源

市場

收入

資產負債表

現金流量

年度

每季

NWPHF 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
營收	59	51	9	6	5	5
營收年增率 (YoY)	883%	467%	50%	20%	0%	-28.99%
營收成本	1	0	0	0	0	0
毛利	58	50	8	5	5	4
銷售、一般及管理費用	11	11	7	7	7	8
研發	12	12	12	11	10	15
營業費用	23	24	20	18	18	23
其他非營業收入 (費用)	0	0	0	0	0	0
稅前淨利	30	21	-16	-17	-14	-19
所得稅費用	5	5	0	0	0	1
淨利	25	15	-16	-17	-14	-20
淨利成長	-239%	-194%	-6%	21%	-30%	0%
稀釋後流通股數	19.96	18.56	17.84	17.84	17.84	17.84
股數年變動 (YoY)	8%	4%	0%	0%	0%	0%
每股盈餘 (稀釋)	1.26	0.85	-0.9	-0.98	-0.83	-1.17
每股盈餘成長率	-225%	-194%	-7%	17%	-28.99%	4%
自由現金流	24	-17	-10	-11	-11	-15
每股自由現金流	--	--	--	--	--	--
毛利率	98.3%	98.03%	88.88%	83.33%	100%	80%
營業利益率	59.32%	50.98%	-122.22%	-216.66%	-240%	-360%
淨利率	42.37%	29.41%	-177.77%	-283.33%	-280%	-400%
自由現金流利潤率	40.67%	-33.33%	-111.11%	-183.33%	-220%	-300%
EBITDA	35	26	-11	-13	-12	-18
EBITDA 利潤率	59.32%	50.98%	-122.22%	-216.66%	-240%	-360%
EBITDA 中的折舊與攤銷	0	0	0	0	0	0
EBIT	35	26	-11	-13	-12	-18
EBIT 利潤率	59.32%	50.98%	-122.22%	-216.66%	-240%	-360%
有效稅率	16.66%	23.8%	0%	0%	0%	-5.26%

Follow-Up Questions

Newron Pharmaceuticals SpA 的關鍵財務報表是什麼？



根據最新的財務報表（Form-10K），Newron Pharmaceuticals SpA 的總資產為 $63，淨isProfitable}為 $15

NWPHF 的關鍵財務比率是什麼？



Newron Pharmaceuticals SpA 的流動比率為 1.01，淨利潤率為 29.41，每股銷售為 $2.74。

Newron Pharmaceuticals SpA 的收入按細分市場或地理位置如何劃分？



Newron Pharmaceuticals SpA 最大收入來源為 Pharmaceutical Drugs，在最近的收益報告中收入為 8,799,296。就地區而言，Italy & United States 是 Newron Pharmaceuticals SpA 的主要市場，收入為 8,799,296。

Newron Pharmaceuticals SpA 是否盈利？



是的，根據最新的財務報表，Newron Pharmaceuticals SpA 的淨利潤為 $15

Newron Pharmaceuticals SpA 有負債嗎？



是的，Newron Pharmaceuticals SpA 的負債為 62

Newron Pharmaceuticals SpA 的流通股有多少？



Newron Pharmaceuticals SpA 的總流通股為 19.95

Newron Pharmaceuticals SpA (NWPHF) 財務

NWPHF 股價走勢圖